Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Control group:Conventional treatment
experimental group:Xiyanping injection+ conventional treatment
Sponsors
Shanghai Public Health Clinical Center
Eligibility
Sex/Gender
All
Age
No minimum to 100 Years
Inclusion criteria
Inclusion criteria: 1. Laboratory examination (RT-PCR) confirms the infection 2019-nCoV, which meets the diagnostic criteria for pneumonia (common type) in the New Coronavirus Infection Pneumonia Diagnosis and Treatment Program (Trial Version 6); 2. The patient has a complete hospitalization record that can be used for research.
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following criteria cannot be enrolled: 1. Suffering from diseases that need to be distinguished from pneumonia infected with new coronavirus, such as tuberculosis, bacterial or viral pneumonia other than new coronavirus pneumonia, hospital-acquired pneumonia, and other pathogenic microorganisms pneumonia; 2. People with basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory tract malformations, abnormal lung development, aspiration pneumonia, and lung malignant tumors; 3. According to the judgment of the investigator, the previous or current disease may affect the patient's participation in the trial or the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; presently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or blood system, or splenectomy, organ transplantation, etc; 4. Pneumonia diagnosed with severe, critically re-associated coronavirus infection or requiring mechanical ventilation or systemic anti-hormonal therapy; 5. Used Chinese patent medicines with similar efficacy as Xiyanping injection during the treatment; 6. The investigator judges that the relevant test or data is missing during the treatment process, which affects the research evaluation or analyst.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical recovery time ; | — |
Countries
China
Contacts
Public ContactHongzhou Lu
Shanghai Public Health Clinical Center
Outcome results
None listed